Summary of COVID-19 razuprotafib studies

1. Files et al., Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial

105 patient razuprotafib late treatment RCT: 10% higher mortality (p=0.81).
RCT severe COVID-19 patients showing no significant difference in outcomes with razuprotafib.
Mar 2023, eClinicalMedicine, https://www.sciencedirect.com/science/article/pii/S2589537023000664, https://c19p.org/filesraz

2. Paggiarino et al., Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

31 patient razuprotafib late treatment RCT: 178% higher progression (p=0.37) and 469% lower hospital discharge (p=0.28).
RCT 29 patients showing no significant differences with razuprotafib treatment.
Feb 2021, NCT04511650, https://clinicaltrials.gov/study/NCT04511650, https://c19p.org/paggiarino